SALL1 functions as a tumor suppressor in hepatocellular carcinoma cells.

Biochem Biophys Res Commun

Laboratoy of Metabolism, Division of Molecular Science, Graduate School of Science and Technology, Gunma University, Kiryu, Gunma 376-8515, Japan; Graduate School of Food and Population Health Sciences, Gunma University, Kiryu, Gunma 376-8515, Japan; Gunma University Center for Food Science and Well

Published: September 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Hepatocyte nuclear factor 4α (HNF4α) is highly expressed in the liver and acts as a master regulator of liver-specific functions and maintenance of differentiated status. Liver-specific Hnf4a-deficient mice (Hnf4a mice) exhibit numerous phenotypes resulting from marked changes in the expression of several hepatic genes. In this study, we found that the mRNA and protein expression of hepatic Spalt-like transcription factor 1 (SALL1), which is important for kidney development, was significantly increased in Hnf4a mice. Protein expression levels of SALL1 were relatively low in control Hnf4a-floxed mice (Hnf4a mice), whereas SALL1 mRNA was highly expressed in both normal human liver and kidney. SALL1 mRNA expression was negatively regulated by miR-192-5p and miR-194-5p, which are direct targets of HNF4α, via binding sites of both miRNAs in the coding and 3'-untranslated regions, respectively. Transient overexpression of SALL1 suppressed the proliferation of human hepatocellular carcinoma (HCC) cell lines. RNA sequencing of HCC cells with SALL1 knockdown and promoter analysis revealed that SALL1 positively regulates A-kinase anchoring protein 12 and insulin-like growth factor binding protein 1 and negatively regulates phosphoserine aminotransferase 1. Stable expression of SALL1 in HCC cells induced cellular senescence-like features, as evidenced by cell hypertrophy, increased senescence-associated β-galactosidase-positive cells, and cell cycle arrest at the S phase. Furthermore, stable expression of SALL1 in HCC cells induced the expression of certain liver-specific markers, indicating that SALL1 promotes redifferentiation of HCC cells. These findings suggest that SALL1 may function as a tumor suppressor in HCC and contribute to the development of HCC therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2025.152385DOI Listing

Publication Analysis

Top Keywords

hcc cells
16
sall1
12
hnf4a mice
12
tumor suppressor
8
hepatocellular carcinoma
8
highly expressed
8
mice hnf4a
8
expression hepatic
8
protein expression
8
sall1 mrna
8

Similar Publications

This study aimed to create multifunctional nanoparticles (NPs), specifically AS1411@MPDA-Len-Cy5.5 (AMLC), for the purpose of developing effective strategies for treating hepatocellular carcinoma (HCC) through targeted therapy and photothermal therapy (PTT). The study involved synthesizing mesoporous polydopamine (MPDA)-NPs, loading lenvatinib (Len) and Cy5.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is a prevalent malignant neoplasm of the digestive system, including 80% of primary liver malignancies. The Wnt/β-catenin signaling pathway plays a key role in immune response and tumer resistance. A growing number of studies have shown that the Wnt/β-catenin signaling pathway is involved in the pathogenesis of HCC.

View Article and Find Full Text PDF

vtRNA1-1 drives regorafenib resistance by sustaining cancer stemness via impaired autophagy and altered svRNA biogenesis.

Int J Biol Macromol

September 2025

Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No.100 Haining Road, Shanghai, 200080, PR China; Shanghai Eye Diseases Prevention &Treatment Center/Shanghai Eye Hospital, School of Medicine, Tongji University, PR China. Electronic address

While vault RNA1-1 (vtRNA1-1) has been implicated in tumor biology, its specific role in cancer stemness and regorafenib resistance remains unexplored. In this study, we identify vtRNA1-1 as a critical regulator of cancer stemness and chemoresistance in Hepatocellular carcinoma (HCC). vtRNA1-1 enhances stemness properties by modulating the nuclear accumulation of Nanog, a core transcription factor.

View Article and Find Full Text PDF

Objective: To investigate the mechanism by which C5ORF13 promotes epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC) through interaction with eukaryotic translation initiation factor 6 (eIF6) and its clinical significance, and to identify the potential use of valproic acid (VPA) as an eIF6 inhibitor in HCC.

Methods: The expression of C5ORF13 in HCC and its prognostic impact were analyzed using GEPIA, UALCAN, and The HUMAN PROTEIN ATLAS databases. Lentiviral transfection technology was used to knock down or overexpress C5ORF13 and eIF6.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC) frequently invades the portal vein, leading to early recurrence and a poor prognosis. However, the mechanisms underlying this invasion remain unclear. In this study, we aimed to detect portal vein circulating tumor cells (CTCs) using a Glypican-3-positive detection method and evaluate their prognostic significance.

View Article and Find Full Text PDF